DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target to $115 ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to ...

在2024年，该公司在美国发布了最新版本的G系列——G7。DexCom在7月底发布第二财季业绩后，股价大幅下跌，但从长期表现来看，这一下跌并不算异常。考虑DexCom从2005年到2018年的表现可以看出。DexCom的股价曾多次大幅下跌，但其中一个 ...

Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024. Alphatec (ATEC) witnessed a jump in share price last session on above ...

and share price spikes are harder to achieve. It is not Dexcom's fault that the market bought into the CGM story and sent shares spiking >$150 – valuing the company at >$50bn – more than three ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of $104.00 ... shown significant progress with its continuous glucose monitoring (CGM) systems, maintaining a ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.